New findings with old drugs for osteoporosis

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 3, 2009, Pages 513-516

  Doggrell, Sheila A ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Clinical trials; Postmenopausal osteoporosis; Strontium ranelate; Tibolone

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CITRATE CALCIUM; COLECALCIFEROL; ESTROGEN; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TIBOLONE; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; ORGANOMETALLIC COMPOUND; PREGNANE DERIVATIVE; THIOPHENE DERIVATIVE;

ARTICLE; BEDTIME DOSAGE; BREAST CANCER; CLINICAL EVALUATION; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPLASIA; ENDOMETRIAL DISEASE; FRAGILITY FRACTURE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; LONG TERM CARE; POSTMENOPAUSE OSTEOPOROSIS; STROKE; TREATMENT OUTCOME; VAGINA BLEEDING; VERTEBRA FRACTURE; CHEMICALLY INDUCED DISORDER; FEMALE; REVIEW;

BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; FEMALE; HUMANS; NORPREGNENES; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; STROKE; THIOPHENES;

EID: 65649154423     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802707887     Document Type: Article

References (17)

1. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 2006;194:S3-11 (Pubitemid 43152482)
2. Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427 (Pubitemid 36999703)
3. Opatrny L, Dell'Aniello S, Assouline S, Suissa S. Hormone replacement therapy use and variations in the risk of breast cancer. BJOG 2008;115:169-175 (Pubitemid 350233601)
4. Available from: http://www.worldhealth.net/news/strontium-breakthrough- against-osteoporo
5. Bjarnason NH, Bjarnason K, Haarbo J, et al. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996;81:2419-2422 (Pubitemid 26240254)
6. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in old postmenopausal women. N Engl J Med 2008;359:697-708
7. Meunier P, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:359-368 (Pubitemid 38133766)
8. Marquis P, Roux C, de la Loge C, et al. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteoporos Int 2008;19:503-510
9. Reginster JW, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 2005;90:2816-2822 (Pubitemid 40686329)
10. Roux C, Reginster YT, Fechtenbaum J, et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 2006;21:536-542
11. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment of the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:1687-1695 (Pubitemid 351847521)
12. Siris ES, Brenneman SK, Miller PD, et al. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and older: resultf for the National Osteoporosis Risk Assessment (NORA). J Bone Miner Res 2004;19:1215-1220 (Pubitemid 41094361)
13. Roux C, Fechtenbaum J, Kolta S, et al. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis doi:10.1136/ard.2008.094516
14. Mosca L, Grady D, Barrett-Connor E, et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke [Epub ahead of print]
15. Bushnell C. The cerebrovascular risks associated with tamoxifen use. Expert Opin Drug Saf 2005;4:501-507 (Pubitemid 40723723)
16. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822 (Pubitemid 46698462)
17. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197-213 (Pubitemid 351665507)